Superworth

Pacific Biosciences of California price to sales ratio PACB

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
4.1×
10-year median
7.1×
Against its 10-year history
32nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.8× to 114×
Peer median
5.5×

Pacific Biosciences of California's price to sales ratio is 4.1× as of Oct 23, 2026.

That is below its ten-year median of 7.1×, lower than on 68% of days in the last ten years.

Over that time it ranged from 1.8× in Jul 2024 to 114× in Feb 2021.

The median for 6 diagnostics and research stocks of a similar size is 5.5×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.1×2.2×5.0×
20253.5×1.8×4.7×
20242.9×1.8×14.8×
202315.5×10.3×25.7×
202213.5×7.1×30.4×
202137.1×37.1×114×
202058.7×4.5×61.4×
20199.7×8.7×14.9×
201813.0×2.9×13.9×
20173.3×3.1×6.5×
20163.5×3.5×13.5×
201513.8×3.7×13.9×
201410.6×8.7×19.1×
201313.7×3.3×18.0×
20122.9×1.7×3.3×

Against its peers

Companies in Medical - Diagnostics & Research nearest Pacific Biosciences of California's size, closest first, today.

CompanyPrice to sales ratio
PACBPacific Biosciences of California4.1×
NRCNRC Health3.5×
CDNACareDx7.8×
VCYTVeracyte6.9×
ICCCImmucell3.0×
BLLNBillionToOne12.8×
LNTHLantheus4.2×
Peer median5.5×

Where Pacific Biosciences of California ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Pacific Biosciences of California

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.